



## CONTROVERSY SESSION

Can adaptive design help to proceed in clinical trials in lung cancer?

Chairs:

David Carbone, Columbus, OH, United States of America and  
Enriqueta Felip, Barcelona, Spain

15-18 April 2015, Geneva, Switzerland

ORGANISERS



PARTNERS





## Question 1

**Adaptive design in clinical trials is useful when a certain drug is analysed in patients with a specific molecular alteration**

- 1. Yes
- 2. No
- 3. Don't know



## Question 2

**Adaptive design in clinical trials is useful in  
registration / pivotal randomised trials**

1. Yes
2. No
3. Don't know



## Question 3

**Adaptive design in clinical trials will reduce the time needed to approve a novel compound**

1. Yes
2. No
3. Don't know



## Question 4

**Adaptive design in clinical trials will increase the probability of positive studies**

1. Yes
2. No
3. Don't know



## Question 5

**Adaptive randomisation in clinical trials is ethically preferable to 1:1 randomisation**

1. Yes
2. No
3. Don't know



## Question 6

**The results of in clinical trials using adaptive designs are more difficult to interpret than the results of simpler designs**

1. Yes
2. No
3. Don't know



## Question 7

**Adaptive designs use fewer patients to answer the same clinical questions**

1. Yes
2. No
3. Don't know





## Question 8

**Adaptive designs are easier to conduct in practice**

1. Yes
2. No
3. Don't know



## Question 9

**Adaptive designs are appropriate for all phases of drug development**

1. Yes
2. No
3. Don't know